Document Detail

Hemostatic and fibrinolytic effects of systemic prostaglandin E1 therapy in patients with peripheral arterial disease.
MedLine Citation:
PMID:  14524034     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The study was designed to evaluate if there is any evidence of a hyperfibrinolytic bleeding-risk under systemic treatment with prostaglandin E1 (PGE1) of patients with peripheral arterial disease (PAD).
PATIENTS AND METHODS: The in vivo effect of PGE1 on the fibrinolytic and hemostatic process was tested on 15 patients before and after treatment with Alprostadil for 21 days using D-dimers (DD), fibrinogen, prothrombin time (PT), partial thromboplastin time (PTT), antithrombin (AT), ProC-Global, plasminogen, plasminogen activator inhibitor activity (PAI), alpha 2-antiplasmin, coagulation factor XII, basal and activated fibrinolytic capacity (fib. cap.).
RESULTS: There was no significant difference in DD, fibrinogen, PT, PTT, AT, ProC-Global, plasminogen, PAI, alpha 2-antiplasmin, coagulation factor XII, basal and activated fibrinolytic capacity observed after the treatment.
CONCLUSION: Summarizing this study there is no hyperfibrinolytic bleeding-risk after the systemic therapy with Alprostadil to be expected.
M Kuss; H Heidrich; E Koettgen
Related Documents :
16303574 - Bleeding caused by portal hypertension.
24772724 - A study on stroke victims in rajiv gandhi government general hospital, chennai.
23617744 - An international longitudinal registry of patients with atrial fibrillation at risk of ...
23286434 - Acute ischemic cerebrovascular events on antiplatelet therapy: what is the optimal prev...
23695644 - Current state of knowledge on oral anticoagulant reversal using procoagulant factors(ju...
16623974 - Deep neck infection as the main initial presentation of primary head and neck cancer.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  VASA. Zeitschrift für Gefässkrankheiten     Volume:  32     ISSN:  0301-1526     ISO Abbreviation:  VASA     Publication Date:  2003 Aug 
Date Detail:
Created Date:  2003-10-03     Completed Date:  2004-01-15     Revised Date:  2012-10-19    
Medline Journal Info:
Nlm Unique ID:  0317051     Medline TA:  Vasa     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  145-8     Citation Subset:  IM    
Institut für Laboratoriumsmedizin und Pathobiochemie, Medizinischen Fakultät Charité, Humboldt-Universität zu Berlin, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Alprostadil / administration & dosage,  adverse effects*
Arterial Occlusive Diseases / blood,  drug therapy*
Blood Coagulation Factors / metabolism
Blood Coagulation Tests
Fibrinolysis / drug effects*
Fibrinolytic Agents / adverse effects*
Hemorrhage / blood,  chemically induced*
Hemostasis / drug effects*
Infusions, Intravenous
Middle Aged
Risk Assessment
Reg. No./Substance:
0/Blood Coagulation Factors; 0/Fibrinolytic Agents; 745-65-3/Alprostadil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Association between endothelial dysfunction and major cardiovascular events in peripheral arterial d...
Next Document:  Surgical treatment of vasculo-Behçet's disease. A review of patients with concomitant multiple aneu...